1. Home
  2. NAKA vs CRBU Comparison

NAKA vs CRBU Comparison

Compare NAKA & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kindly MD Inc.

NAKA

Kindly MD Inc.

SELL

Current Price

$8.12

Market Cap

152.1M

Sector

N/A

ML Signal

SELL

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$0.46

Market Cap

138.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAKA
CRBU
Founded
2019
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.1M
138.3M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
NAKA
CRBU
Price
$8.12
$0.46
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
★ $13.33
$5.75
AVG Volume (30 Days)
200.1K
★ 4.2M
Earning Date
11-18-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.19
3.64
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$3,833.87
$145.34
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.33
$0.44
52 Week High
$840.00
$3.53

Technical Indicators

Market Signals
Indicator
NAKA
CRBU
Relative Strength Index (RSI) 44.48 12.95
Support Level $4.38 N/A
Resistance Level $10.40 $1.73
Average True Range (ATR) 0.66 0.06
MACD -0.27 -0.06
Stochastic Oscillator 18.18 2.21

Price Performance

Historical Comparison
NAKA
CRBU

About NAKA Kindly MD Inc.

Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: